Similar Papers

Paper Title
Journal
Date
Author
The in Vivo Profile of CT133, a Potent, Well Tolerated, and Selective CRTH2 Antagonist for the Treatment of Allergic Asthma and Rhinitis
Dan Guo
Journal of Allergy and Clinical Immunology | VOL. 135
Dan GuoDan Guo
01 Feb 2015
Health economics of allergen-specific immunotherapy in the United States
Richard F Lockey ... Cheryl S Hankin
Journal of Allergy and Clinical Immunology | VOL. 127
Richard F Lockey, et. al.Richard F Lockey ... Cheryl S Hankin
01 Jan 2010
The evidence for commercial house dust mite immunotherapy products: A pragmatic systematic review with narrative synthesis
Timothy West ... Constance H Katelaris
Journal of Allergy and Clinical Immunology: Global | VOL. 3
Timothy West, et. al.Timothy West ... Constance H Katelaris
10 Apr 2024
Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis
R Félix Toledo ... J.C Miralles López
Allergologia et Immunopathologia | VOL. 30
R Félix Toledo, et. al.R Félix Toledo ... J.C Miralles López
01 Jan 2002
View more papers

More From: BioDrugs

Paper Title
Journal
Date
Author
Acknowledgement to Referees
-
BioDrugs | VOL. -
--
24 Dec 2024
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching.
Hillel P Cohen ... Wolfram Bodenmueller
BioDrugs | VOL. 38
Hillel P Cohen, et. al.Hillel P Cohen ... Wolfram Bodenmueller
23 Mar 2024
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Paola Maria Cutroneo ... Fabiana Furci
BioDrugs | VOL. 38
Paola Maria Cutroneo, et. al.Paola Maria Cutroneo ... Fabiana Furci
15 Mar 2024
Use of Biosimilars: A Systematic Review of Published Position Statements and Recommendations from Health Organisations and Societies.
Noraisyah Mohd Sani ... Zoriah Aziz
BioDrugs | VOL. 38
Noraisyah Mohd Sani, et. al.Noraisyah Mohd Sani ... Zoriah Aziz
12 Mar 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.